Raza A, Maheshwari Y, Ucar K, Mayers G, Preisler H D
Acta Haematol. 1987;77(3):140-5. doi: 10.1159/000205978.
The proliferative characteristics of myeloid leukemias were defined in vivo following intravenous bromodeoxyuridine (BrdU). Fifteen patients received a 2-hour infusion of BrdU. A monoclonal anti-BrdU antibody was used to detect the in vivo incorporation of BrdU by S-phase cells. The percentage of S-phase cells obtained from the biopsies (mean 17.3%) was significantly higher (p = 0.00001) than the percentage determined from the aspirates (7.8%). It is concluded that the true estimate of S-phase cells can only be obtained from biopsies following in vivo labeling of cells synthesizing DNA. The persistence of BrdU-labeled cells in follow-up studies can be used to recognize 'residual leukemia', and the subsequent fate of these cells can be defined in vivo.
在静脉注射溴脱氧尿苷（BrdU）后，在体内确定了髓系白血病的增殖特征。15名患者接受了2小时的BrdU输注。使用单克隆抗BrdU抗体检测S期细胞在体内对BrdU的掺入情况。从活检样本中获得的S期细胞百分比（平均17.3%）显著高于（p = 0.00001）从抽吸物中确定的百分比（7.8%）。结论是，只有在对合成DNA的细胞进行体内标记后，通过活检才能获得S期细胞的真实估计值。在后续研究中，BrdU标记细胞的持续存在可用于识别“残留白血病”，并且这些细胞的后续命运可在体内确定。
